Christopher Raymond
Stock Analyst at Piper Sandler
(0)
# 4223
Out of 5,243 analysts
142
Total ratings
40.43%
Success rate
-8.08%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Ultragenyx Pharmaceu... | Maintains: Overweight | 135 140 | 41.88 | 234.29% | 5 | Jan 13, 2025 | |
Inozyme Pharma | Maintains: Overweight | 43 30 | 1.42 | 2012.68% | 1 | Jan 13, 2025 | |
Monopar Therapeutics | Initiates Coverage On: Overweight | 72 | 25.45 | 182.91% | 1 | Jan 10, 2025 | |
Biogen | Downgrades: Neutral | 315 138 | 142.75 | -3.33% | 15 | Jan 2, 2025 | |
AbbVie | Maintains: Overweight | 212 220 | 171.11 | 28.57% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 85 20 | 3.19 | 526.96% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 3 13 | 2.47 | 426.32% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 4 5 | 0.63 | 693.65% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 1242 1195 | 705.59 | 69.36% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 66 76 | 36.22 | 109.83% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 107 122 | 62.28 | 95.89% | 11 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 10 | 0.79 | 1165.82% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 33 | 17.19 | 91.97% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 500 535 | 421.26 | 27% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 9 7 | 1.66 | 321.69% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 15 | 5.46 | 174.73% | 6 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 78 104 | 106.33 | -2.19% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 42 | 6.36 | 560.38% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 11 21 | 1.66 | 1165.06% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 27 2 | 0.41 | 265.85% | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 18 23 | n/a | n/a | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 4 | n/a | n/a | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22 | 8.08 | 172.28% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 2 4 | 1.92 | 108.33% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 17 | n/a | n/a | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 25 | 5.77 | 333.28% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 293 288 | 269.8 | 6.75% | 11 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 41 | 33.86 | 21.09% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 3 1 | n/a | n/a | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 6 2 | n/a | n/a | 3 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 28 | 55.16 | -49.24% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 12 | n/a | n/a | 2 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 56 28 | n/a | n/a | 4 | May 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 146 180 | n/a | n/a | 2 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | 76.4 | -47.64% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 90 | 3.22 | 2695.03% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | n/a | n/a | n/a | 3 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 60 35 | n/a | n/a | 1 | Aug 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | n/a | n/a | 1 | Apr 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 96 | 1.85 | 5089.19% | 2 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 170 | n/a | n/a | 1 | Oct 23, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Neutral | 133 | n/a | n/a | 2 | Oct 23, 2017 |